• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性膀胱癌中PTEN和MXI1的分子分析。

Molecular analysis of PTEN and MXI1 in primary bladder carcinoma.

作者信息

Wang D S, Rieger-Christ K, Latini J M, Moinzadeh A, Stoffel J, Pezza J A, Saini K, Libertino J A, Summerhayes I C

机构信息

Department of Urology, Lahey Clinic, Burlington, MA, USA.

出版信息

Int J Cancer. 2000 Nov 15;88(4):620-5. doi: 10.1002/1097-0215(20001115)88:4<620::aid-ijc16>3.0.co;2-z.

DOI:10.1002/1097-0215(20001115)88:4<620::aid-ijc16>3.0.co;2-z
PMID:11058880
Abstract

Loss of heterozygosity (LOH) on 10q is associated with late-stage events in urothelial neoplastic progression. The tumor suppressor gene PTEN, which is mutated or homozygously deleted in numerous cancers, maps to a region of 10q within the reported region of minimal loss in bladder tumors. In two recent studies alterations in the PTEN gene occur at a low frequency in bladder tumors displaying 10q LOH. We have screened 35 late-stage bladder tumors for mutations in PTEN and MXI1, both genes mapping to chromosome 10q. Using single-strand conformation polymorphism analysis, we identified 6 tumors harboring mutations in PTEN and 2 additional tumors displaying homozygous deletion at this locus. No MXI1 mutations were identified within the same tumor panel. Of 16 bladder tumor cell lines analyzed, 2 showed homozygous deletion of PTEN and 3 harbored point mutations resulting in an amino acid change. Two cell lines harbored missense mutations in MXI1. We report a significantly higher frequency of PTEN alterations in bladder carcinoma (23%) than was previously recorded, with no accompanying mutations in the MXI1 gene.

摘要

10号染色体长臂杂合性缺失(LOH)与尿路上皮肿瘤进展的晚期事件相关。肿瘤抑制基因PTEN在众多癌症中发生突变或纯合缺失,定位于膀胱肿瘤最小缺失报道区域内的10q区域。在最近的两项研究中,PTEN基因改变在显示10q LOH的膀胱肿瘤中发生频率较低。我们筛查了35例晚期膀胱肿瘤中的PTEN和MXI1基因的突变,这两个基因均定位于10号染色体长臂。通过单链构象多态性分析,我们鉴定出6例携带PTEN突变的肿瘤以及另外2例在该位点显示纯合缺失的肿瘤。在同一肿瘤组中未鉴定出MXI1突变。在分析的16株膀胱肿瘤细胞系中,2株显示PTEN纯合缺失,3株存在导致氨基酸改变的点突变。2株细胞系在MXI1中存在错义突变。我们报道膀胱癌中PTEN改变的频率(23%)显著高于先前记录,且MXI1基因无伴随突变。

相似文献

1
Molecular analysis of PTEN and MXI1 in primary bladder carcinoma.原发性膀胱癌中PTEN和MXI1的分子分析。
Int J Cancer. 2000 Nov 15;88(4):620-5. doi: 10.1002/1097-0215(20001115)88:4<620::aid-ijc16>3.0.co;2-z.
2
Somatic mutation of PTEN in bladder carcinoma.膀胱癌中PTEN的体细胞突变。
Br J Cancer. 1999 May;80(5-6):904-8. doi: 10.1038/sj.bjc.6690439.
3
Microsatellite deletion mapping on chromosome 10q and mutation analysis of MMAC1, FAS, and MXI1 in human glioblastoma multiforme.人多形性胶质母细胞瘤中10号染色体q臂的微卫星缺失定位及MMAC1、FAS和MXI1的突变分析。
Int J Oncol. 1998 Apr;12(4):905-10. doi: 10.3892/ijo.12.4.905.
4
Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers.原发性膀胱癌中PTEN/MMAC1的点突变和纯合缺失
Oncogene. 1998 Jun 18;16(24):3215-8. doi: 10.1038/sj.onc.1201855.
5
The MXI1 tumor suppressor gene is not mutated in primary prostate cancer.MXI1肿瘤抑制基因在原发性前列腺癌中未发生突变。
Oncol Rep. 1998 Jan-Feb;5(1):213-6.
6
Point mutations of the Mxil gene are rare in prostate cancers.Mxil基因的点突变在前列腺癌中较为罕见。
Prostate. 1996 Sep;29(3):191-3. doi: 10.1002/1097-0045(199609)29:3<191::aid-pros2990290305>3.0.co;2-1.
7
Mxi1 is a potential cellular target of carcinogens and frequently mutated in experimental rat tumors and tumor cell lines.Mxi1是致癌物的潜在细胞靶点,在实验大鼠肿瘤和肿瘤细胞系中经常发生突变。
Pathol Int. 2000 May;50(5):373-83. doi: 10.1046/j.1440-1827.2000.01057.x.
8
PTEN mutations in endometrial cancers with 10q LOH: additional evidence for the involvement of multiple tumor suppressors.伴有10号染色体长臂杂合性缺失的子宫内膜癌中的PTEN突变:多种肿瘤抑制基因参与的更多证据
Gynecol Oncol. 1998 Dec;71(3):391-5. doi: 10.1006/gyno.1998.5208.
9
PTEN and MXI1 allelic loss on chromosome 10q is rare in melanoma in vivo.
Arch Dermatol Res. 1999 Oct;291(10):567-9. doi: 10.1007/s004030050456.
10
Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas.排除PTEN肿瘤抑制基因在乳腺癌中起主要作用的可能性。
Br J Cancer. 1999 Feb;79(5-6):754-8. doi: 10.1038/sj.bjc.6690121.

引用本文的文献

1
USP13 functions as a tumor suppressor by blocking the NF-kB-mediated PTEN downregulation in human bladder cancer.USP13 通过阻断 NF-κB 介导的 PTEN 下调在人膀胱癌中发挥肿瘤抑制作用。
J Exp Clin Cancer Res. 2019 Jun 14;38(1):259. doi: 10.1186/s13046-019-1262-4.
2
Reduced immunohistochemical PTEN staining is associated with higher progression rate and recurrence episodes in non-invasive low-grade papillary urothelial carcinoma of the bladder.免疫组织化学染色 PTEN 表达减少与非浸润性低级别乳头状膀胱尿路上皮癌的更高进展率和复发频率相关。
Virchows Arch. 2018 Jun;472(6):969-974. doi: 10.1007/s00428-018-2302-8. Epub 2018 Jan 24.
3
Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro.
磷脂酰肌醇-3-激酶抑制剂可诱导人膀胱癌细胞对阿霉素的一种新型衍生物AD198化疗产生体外化学敏感性。
BMC Cancer. 2015 Nov 23;15:927. doi: 10.1186/s12885-015-1930-5.
4
Targeting Hsp90 in urothelial carcinoma.针对尿路上皮癌中的热休克蛋白90
Oncotarget. 2015 Apr 20;6(11):8454-73. doi: 10.18632/oncotarget.3502.
5
Network analysis of microRNAs, genes and their regulation in human bladder cancer.人类膀胱癌中微小RNA、基因及其调控的网络分析
Biomed Rep. 2013 Nov;1(6):918-924. doi: 10.3892/br.2013.157. Epub 2013 Aug 19.
6
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.尿路上皮癌中p85α不同区域突变的鉴定
PLoS One. 2013 Dec 18;8(12):e84411. doi: 10.1371/journal.pone.0084411. eCollection 2013.
7
CSTP1, a novel protein phosphatase, blocks cell cycle, promotes cell apoptosis, and suppresses tumor growth of bladder cancer by directly dephosphorylating Akt at Ser473 site.CSTP1,一种新型的蛋白磷酸酶,通过直接将 Akt 丝氨酸 473 位点去磷酸化来阻滞细胞周期、促进细胞凋亡、抑制膀胱癌肿瘤生长。
PLoS One. 2013 Jun 17;8(6):e65679. doi: 10.1371/journal.pone.0065679. Print 2013.
8
Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells.致癌激活 Pak1 依赖性巨胞饮途径决定了卡介苗进入膀胱癌细胞。
Cancer Res. 2013 Feb 1;73(3):1156-67. doi: 10.1158/0008-5472.CAN-12-1882.
9
The androgen receptor and stem cell pathways in prostate and bladder cancers (review).雄激素受体和干细胞通路在前列腺癌和膀胱癌中的作用(综述)。
Int J Oncol. 2012 Jan;40(1):5-12. doi: 10.3892/ijo.2011.1212. Epub 2011 Sep 28.
10
Phosphatidylinositol 3'-kinase, mTOR, and glycogen synthase kinase-3β mediated regulation of p21 in human urothelial carcinoma cells.磷脂酰肌醇 3-激酶、mTOR 和糖原合成酶激酶-3β 在人尿路上皮癌细胞中对 p21 的调节作用。
BMC Urol. 2011 Aug 24;11:19. doi: 10.1186/1471-2490-11-19.